skip navigation


Register for Latest Research

Stay Informed
Register with NCJRS to receive NCJRS's biweekly e-newsletter JUSTINFO and additional periodic emails from NCJRS and the NCJRS federal sponsors that highlight the latest research published or sponsored by the Office of Justice Programs.

NCJRS Abstract

The document referenced below is part of the NCJRS Virtual Library collection. To conduct further searches of the collection, visit the Virtual Library. See the Obtain Documents page for direction on how to access resources online, via mail, through interlibrary loans, or in a local library.


NCJ Number: 251161 Find in a Library
Title: 2017 Prescription Drug Monitoring Program Introduced and Enacted Legislation and Regulations
Corporate Author: Brandeis University
Florence Heller Graduate School of Social Welfare
United States of America
Date Published: August 2017
Page Count: 88
Sponsoring Agency: Brandeis University
Waltham, MA 02154
Bureau of Justice Assistance
Washington, DC 20531
Grant Number: 2014-PM-BX-K001
Sale Source: Bureau of Justice Assistance
US Dept of Justice
Office of Justice Programs
810 Seventh Street NW
Washington, DC 20531
United States of America
Document: PDF
Type: Legislation/Policy Description; Legislative/Regulatory Material; Report (Grant Sponsored); Report (Technical Assistance)
Format: Document; Document (Online)
Language: English
Country: United States of America
Annotation: This report presents the numbers, provisions, status, and date of last action for Federal and each State’s legislation as of 2017 that pertains to the establishment, responsibilities, and operations of State Prescription Drug Monitoring Programs (PDMPs).
Abstract: At the Federal level, HR 993 was referred to the House Subcommittee on Health in February 2017. This bill, if enacted, would create the Opioid Abuse Prevention and Treatment Act of 2017. It provides that the Secretary of Health and Human Services award grants to one or more States to perform a 1-year pilot project to develop a standardized peer review process and methodology to review and evaluate prescriber and pharmacy dispensing patterns through a review of the State PDMP in the States receiving grants. It further provides that grantee States must make PDMP data available to State regulators and licensing boards regarding those controlled substances for which a prescriber is required to be registered with the Drug Enforcement Administration and may make such information available to State regulators. Federal HR 1854 was referred to the House Subcommittee on Crime, Terrorism, Homeland Security, and Investigations. It would create the “Prescription Drug Monitoring Act of 2017.” This bill pertains to requirements for States receiving grant funds under the Harold Rogers grant program or the controlled substance monitoring program of the Public Health Services Act. Federal SB 778, which is the U.S. Senate version of HR 1854, was referred to the Senate Committee on Health, Education, Labor, and Pensions in March 2017. Information on the aforementioned Federal legislation is followed by a review of each State’s legislation pertinent to the establishment, responsibilities, and operations of the State’s PDMP.
Main Term(s): Drug laws
Index Term(s): BJA Grant-related Documents; BJA Resources; Drug law enforcement; Federal legislation; Federal regulations; Prescription drugs; State laws; State regulations
To cite this abstract, use the following link:

*A link to the full-text document is provided whenever possible. For documents not available online, a link to the publisher's website is provided. Tell us how you use the NCJRS Library and Abstracts Database - send us your feedback.